FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutical industry, namely to a pharmaceutical combination and use of said combination for preventing or treating cancer. Pharmaceutical combination for preventing or treating cancer, containing as active ingredients: a naphthoquinone compound and at least one selected from an immune checkpoint inhibitor (ICI) and an immunogenic cell death inducer (ICD), where the naphthoquinone-based compound is dannion (2,3,3-trimethyl-2H-benzo[g][1]benzofuran-4,5-dione), where the immune checkpoint inhibitor is selected from the group consisting of anti-CTLA4 antibody, anti-PD-L1 antibody, anti-PD-1 antibody, anti-PD-L2 antibody, anti-LAG3 antibody, anti-B7-H3 antibody, anti-B7-H4 antibodies, anti-HVEM antibodies, anti-KIR antibodies, anti-OX40 antibodies, anti-IgG antibodies, anti-IDO-1 antibodies, anti-IDO-2 antibodies, anti-CEACAM1 antibodies, anti-BTLA antibodies, anti-OX40L antibodies, anti-TIM3 antibodies, anti-GAL9 antibodies, anti-VISTA antibodies, anti-TIGIT antibodies and combinations thereof, where the immunogenic cell death inducer is selected from the group, consisting of capecitabine, 5-fluorouracil, thioguanine, chlorambucil, oxaliplatin, cisplatin, carboplatin, paclitaxel, docetaxel, irinotecan, doxorubicin, vinorelbine, gemcitabine, pemetrexed, adriamycin, etoposide, vincristine, cytarabine, cyclophosphamide, ifosfamide, tamoxifen, anastrozole, letrozole, exemestane, fulvestrant, temozolomide, carmustine, lomustine, epirubicine, eribulin, toremifene, goserelin, megestrol, vinblastine, bendamustine, thiotepa, bleomycin, topotecan, leucovorin, trifluridine, tipiracil, mitoxantrone, mitomycin C, aldesleukin, temsirolimus, everolimus, mechlorethamine, methotrexate, trastuzumab, bevacizumab, cetuximab, aflibercept, pertuzumab, ramucirumab, panitumumab, nivolumab, necitumumab, pembrolizumab, obinutuzumab, ofatumumab, erlotinib, gefitinib, sorafenib, lapatinib, dinacyclib, palbociclib, regorafenib, imatinib, sunitinib, axitinib, pazopanib, afatinib, ceritinib, crizotinib, osimertinib, bozutinib, dasatinib, nilotinib, ponatinib, hydroxyurea, procarbazine, abemaciclib, wistusertib and combinations thereof, where the weight ratio per dose of the naphthoquinone-based compound and the immune checkpoint inhibitor ranges from 200:1 to 2.5:1 and where the weight ratio per dose of the naphthoquinone-based compound and the immunogenic cell death inducer ranges from 1:0.001 to 0.001:1.
EFFECT: use of the group of inventions provides effective inhibition of cancer cell proliferation due to the combined introduction of a naphthoquinone-based compound in a combination with an immune checkpoint inhibitor and/or an immunogenic cell death inducer, wherein said combination has a synergistic anticancer effect.
9 cl, 46 dwg, 42 tbl, 6 ex
